PODD logo
PODD
Insulet

FDA Clearance And Global Rollout Of Omnipod 5 Will Expand Market Reach

AN
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Consensus Narrative from 23 Analysts
Published
22 Aug 24
Updated
30 Jul 25
AnalystConsensusTarget's Fair Value
US$340.13
15.4% undervalued intrinsic discount
30 Jul
US$287.77
Loading
1Y
51.0%
7D
-1.5%

Author's Valuation

US$340.1

15.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates9

Shared on07 May 25
Fair value Increased 4.03%

Read more

Shared on30 Apr 25
Fair value Decreased 0.04%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25
Fair value Decreased 0.21%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25
Fair value Decreased 0.36%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Increased 5.92%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on10 Mar 25
Fair value Decreased 7.80%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more